title: A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma.
abstract: The purpose of this study was to evaluate the activity of single-agent bevacizumab in patients with recurrent anaplastic glioma and assess correlative advanced imaging parameters. Patients with recurrent anaplastic glioma were treated with bevacizumab 10 mg/kg every 2 weeks. Complete patient evaluations were repeated every 4 weeks. Correlative dynamic contrast-enhanced MR and (18)fluorodeoxyglucose PET imaging studies were obtained to evaluate physiologic changes in tumor and tumor vasculature at time points including baseline, 96 h after the first dose, and after the first 4 weeks of therapy. Median overall survival was 12 months (95% confidence interval [CI]: 6.08-22.8). Median progression-free survival was 2.93 months (95% CI: 2.01-4.93), and 6-month progression-free survival was 20.9% (95% CI: 10.3%-42.5%). Thirteen (43%) patients achieved a partial response. The most common grade ≥ 3 treatment-related toxicities were hypertension, hypophosphatemia, and thromboembolism. Single-agent bevacizumab produces significant radiographic response in patients with recurrent anaplastic glioma but did not meet the 6-month progression-free survival endpoint. Early change in enhancing tumor volume at 4 days after start of therapy was the most significant prognostic factor for overall and progression-free survival.
authors.affiliation: The Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892, USA. kreislt@mail.nih.gov
authors.forename: Teri N
authors.initials: TN
authors.lastname: Kreisl
authors.forename: Weiting
authors.initials: W
authors.lastname: Zhang
authors.forename: Yazmin
authors.initials: Y
authors.lastname: Odia
authors.forename: Joanna H
authors.initials: JH
authors.lastname: Shih
authors.forename: John A
authors.initials: JA
authors.lastname: Butman
authors.forename: Dima
authors.initials: D
authors.lastname: Hammoud
authors.forename: Fabio M
authors.initials: FM
authors.lastname: Iwamoto
authors.forename: Joohee
authors.initials: J
authors.lastname: Sul
authors.forename: Howard A
authors.initials: HA
authors.lastname: Fine
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D053208:Kaplan-Meier Estimate; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab